Investors & Media

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Flex Pharma to Report Second Quarter 2016 Results on August 3, 2016

BOSTON--(BUSINESS WIRE)--Jul. 27, 2016-- Click to Tweet

Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, announced today that it will report its financial results for the second quarter ended June 30, 2016 on Wednesday, August 3, 2016 before the U.S. financial markets open. The Company will host a conference call and webcast at 8:45 a.m. ET to discuss second quarter 2016 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874 (International).

A live webcast may be accessed in the Investors section of the Company's website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma's website for three months.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps. Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair and CEO Christoph Westphal, M.D., Ph.D.

Visit www.TeamHOTSHOT.com for updates and to learn more about HOTSHOT, the Company’s consumer product which is scientifically proven to prevent and treat muscle cramps.

HOTSHOT is a consumer product that is marketed to endurance athletes for exercise-associated muscle cramps. HOTSHOT complements the Company’s drug development business and is not intended to diagnose, treat, cure or prevent any disease.

Follow Flex Pharma (@flexpharma) and HOTSHOTTM (@Team_HOTSHOT) on Twitter

Source: Flex Pharma, Inc.

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications
irdept@flex-pharma.com